AstraZeneca Quarterly Net Profit Rises 2% On Strong Cancer Drug Sales

British pharmaceutical giant AstraZeneca on Monday said net profit rose in its second quarter, driven once again by strong growth in sales of its cancer drugs.

Profit after tax climbed more than two percent to $2.5 billion in the three months to the end of June, compared with the same period last year, AstraZeneca said in a results statement.